Rapamycin inhibits ox-LDL-induced inflammation in human endothelial cells in vitro by inhibiting the mTORC2/PKC/c-Fos pathway

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Acta Pharmacologica Sinica

• Publication date

  2017-10-26

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/aps.2017.102PMID 29072256PMCID PMC5843827
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanism of PKC activity affecting the adhesion reaction of endothelial cells with monocytes.

  2015cited by this paper
• Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion

  2015cited by this paper
• Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2

  2014cited by this paper
• Medroxyprogesterone acetate enhances monocyte-endothelial interaction under flow conditions by stimulating the expression of cell adhesion molecules.

  2014cited by this paper
• C-Fos Regulation by the MAPK and PKC Pathways in Intervertebral Disc Cells

  2013cited by this paper
• c-FOS suppresses ovarian cancer progression by changing adhesion

  2013cited by this paper
• Inflammation in Atherosclerosis

  2012cited by this paper
• mTOR signaling in growth control and disease.

  2012cited by this paper
• mTOR complex 2 signaling and functions

  2011cited by this paper
• Rapamycin Inhibits Cytoskeleton Reorganization and Cell Motility by Suppressing RhoA Expression and Activity*

  2010cited by this paper
• Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels

  2009cited by this paper
• Role of Junctional Adhesion Molecule-Like Protein in Mediating Monocyte Transendothelial Migration

  2009cited by this paper
• Low‐dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor

  2009cited by this paper
• Everolimus Inhibits Monocyte/Macrophage Migration in Vitro and Their Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits

  2009cited by this paper
• mTOR Inhibitors and Calcineurin Inhibitors Do Not Affect Adhesion Molecule Expression of Human Macro- and Microvascular Endothelial Cells

  2008cited by this paper
• Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling

  2008cited by this paper
• mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).

  2008cited by this paper
• Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins

  2008cited by this paper
• Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling

  2008cited by this paper
• PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase.

  2007cited by this paper
• PRR5, a Novel Component of mTOR Complex 2, Regulates Platelet-derived Growth Factor Receptor β Expression and Signaling*

  2007cited by this paper
• Identification of Protor as a novel Rictor-binding component of mTOR complex-2.

  2007cited by this paper
• Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

  2007cited by this paper
• SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity.

  2006cited by this paper
• Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity.

  2006cited by this paper
• Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

  2006cited by this paper
• Inhibition of mammalian target of rapamycin modulates expression of adhesion molecules in endothelial cells.

  2006cited by this paper
• mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s.

  2006cited by this paper
• Essential Roles of Lipoxygenases in LDL Oxidation and Development of Atherosclerosis

  2005cited by this paper
• Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

  2005cited by this paper
• Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients With In-Stent Restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) Trial

  2004cited by this paper
• Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

  2004cited by this paper
• Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

  2004cited by this paper
• Autocrine Transforming Growth Factor α Regulates Cell Adhesion by Multiple Signaling via Specific Phosphorylation Sites of p70S6 Kinase in Colon Cancer Cells*

  2004cited by this paper
• Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study

  2003cited by this paper
• GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR.

  2003cited by this paper
• mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

  2002cited by this paper
• A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

  2002cited by this paper
• A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION

  2002cited by this paper
• Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control.

  2002cited by this paper
• Inflammation in atherosclerosis

  2002cited by this paper
• Intravascular ultrasound study on in-stent restenosis

  2002cited by this paper
• Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.

  2002cited by this paper
• Studies on the mechanism of resistance to rapamycin in human cancer cells.

  1998cited by this paper
• Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.

  1995cited by this paper
• Rapamycin: A novel immunosuppressive macrolide

  1994cited by this paper
• Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules.

  1993cited by this paper
• Endothelial damage and thrombocyte adhesion in pigeon atherosclerosis.

  1977cited by this paper

• The mTOR Signaling Pathway: Key Regulator and Therapeutic Target for Heart Disease

  2025cites this paper
• Autophagy–senescence interplay in kidney disease: mechanistic insights and therapeutic potential

  2025cites this paper
• The perspective of modern transplant science – transplant arteriosclerosis: inspiration derived from mitochondria associated endoplasmic reticulum membrane dysfunction in arterial diseases

  2025cites this paper
• Tacrolimus combined with arsenic trioxide provides a three-in-one drug-eluting coronary stent integrating anti-restenosis, pro-endothelialization and anti-inflammation

  2024cites this paper
• Extracellular vesicle-derived miR-146a as a novel crosstalk mechanism for high-fat induced atherosclerosis by targeting SMAD4

  2024cites this paper
• PI3K signaling promotes formation of lipid-laden foamy macrophages at the spinal cord injury site

  2023cites this paper
• Oxidative Stress Induces E-Selectin Expression through Repression of Endothelial Transcription Factor ERG.

  2023cites this paper
• Combining network pharmacology and bioinformatics to identify bioactive compounds and potential mechanisms of action of Sedum aizoon L in the treatment of atherosclerosis

  2023cites this paper
• Research Progress and Molecular Mechanisms of Endothelial Cells Inflammation in Vascular-Related Diseases

  2023cites this paper
• Effective Attenuation of Arteriosclerosis Following Lymphatic-Targeted Delivery of Hyaluronic Acid-Decorated Rapamycin Liposomes

  2023cites this paper
• Overexpression of MiR-181c-5p Attenuates Human Umbilical Vascular Endothelial Cell Injury in Deep Vein Thrombosis by Targeting FOS.

  2023cites this paper
• Reverse tracking from drug-induced transcriptomes through multilayer molecular networks reveals hidden drug targets

  2023cites this paper
• The mammalian target of rapamycin contributes to synovial fibroblast pathogenicity in rheumatoid arthritis

  2023cites this paper
• Identification of potential hub genes and regulatory networks of smoking-related endothelial dysfunction in atherosclerosis using bioinformatics analysis

  2023cites this paper
• The Acid Sphingomyelinase Inhibitor Amitriptyline Ameliorates TNF-α-Induced Endothelial Dysfunction

  2022cites this paper
• Rapamycin ameliorates brain damage and maintains mitochondrial dynamic balance in diabetic rats subjected to middle cerebral artery occlusion

  2022cites this paper
• A circular RNA, circUSP36, accelerates endothelial cell dysfunction in atherosclerosis by adsorbing miR-637 to enhance WNT4 expression

  2021cites this paper
• The mTOR/NF-κB Pathway Mediates Neuroinflammation and Synaptic Plasticity in Diabetic Encephalopathy

  2021cites this paper
• Vascular Endothelial Senescence: Pathobiological Insights, Emerging Long Noncoding RNA Targets, Challenges and Therapeutic Opportunities

  2021cites this paper
• Potential Role of Protein Kinase C in the Pathophysiology of Diabetes-Associated Atherosclerosis

  2021cites this paper
• Oxidized low‐density lipoprotein activates extracellular signal‐regulated kinase signaling to downregulate sortilin expression in liver sinusoidal endothelial cells

  2021cites this paper
• mTOR as the therapeutic target of vascular proliferative diseases: past, present, and future.

  2021cites this paper
• eNOS-NO system contributes to a novel anti-atherogenic effect of Leonurine via inflammation inhibition and plaque stabilization

  2020cites this paper
• Impaired lipophagy in endothelial cells with prolonged exposure to oxidized low-density lipoprotein

  2020cites this paper
• miR-29b-3p inhibits post-infarct cardiac fibrosis by targeting FOS

  2020cites this paper
• Statins use and its impact in EGFR‐TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan

  2020cites this paper
• eNOS-Nitric Oxide System Contributes to a Novel Antiatherogenic Effect of Leonurine via Inflammation Inhibition and Plaque Stabilization

  2020cites this paper
• Long noncoding RNA XXYLT1-AS2 regulates proliferation and adhesion by targeting the RNA binding protein FUS in HUVEC.

  2020cites this paper
• Rapamycin promotes endothelial–mesenchymal transition during stress-induced premature senescence through the activation of autophagy

  2020cites this paper
• The interrupted cross-talk of inflammatory and oxidative stress trajectories signifies the effect of artesunate against hepatic ischemia/reperfusion-induced inflammasomopathy.

  2020cites this paper
• Regulatory Roles of Related Long Non-coding RNAs in the Process of Atherosclerosis

  2020cites this paper
• Rapamycin: A Bacteria-Derived Immunosuppressant That Has Anti-atherosclerotic Effects and Its Clinical Application

  2019cites this paper
• Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer

  2018cites this paper
• Circulating low density lipoprotein (LDL)

  2018cites this paper
• Extracellular vesicles as novel biomarkers and pharmaceutic targets of diseases

  2018cites this paper
• MiR-410 inhibition induces HUVECs proliferation and represses ox-LDL-triggered apoptosis through activating STAT3.

  2018cites this paper
• Oxidized low density lipoprotein induces endothelial-to-mesenchymal transition by stabilizing Snail in human aortic endothelial cells.

  2018cites this paper